JP6788583B2 - 増殖性疾患を処置するためのチアゾリル含有化合物 - Google Patents

増殖性疾患を処置するためのチアゾリル含有化合物 Download PDF

Info

Publication number
JP6788583B2
JP6788583B2 JP2017522375A JP2017522375A JP6788583B2 JP 6788583 B2 JP6788583 B2 JP 6788583B2 JP 2017522375 A JP2017522375 A JP 2017522375A JP 2017522375 A JP2017522375 A JP 2017522375A JP 6788583 B2 JP6788583 B2 JP 6788583B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
optionally substituted
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017522375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537886A (ja
JP2017537886A5 (enExample
Inventor
グレイ，ナサニエル，エス．
バーレージ，サラ，ジーン
トレオン，スティーブン，ピー．
チェ，ファン，グン
ション，ユアン
ヤン，グアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2017537886A publication Critical patent/JP2017537886A/ja
Publication of JP2017537886A5 publication Critical patent/JP2017537886A5/ja
Application granted granted Critical
Publication of JP6788583B2 publication Critical patent/JP6788583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017522375A 2014-10-22 2015-10-22 増殖性疾患を処置するためのチアゾリル含有化合物 Active JP6788583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067178P 2014-10-22 2014-10-22
US62/067,178 2014-10-22
PCT/US2015/056899 WO2016065138A1 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Publications (3)

Publication Number Publication Date
JP2017537886A JP2017537886A (ja) 2017-12-21
JP2017537886A5 JP2017537886A5 (enExample) 2018-11-29
JP6788583B2 true JP6788583B2 (ja) 2020-11-25

Family

ID=55761545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522375A Active JP6788583B2 (ja) 2014-10-22 2015-10-22 増殖性疾患を処置するためのチアゾリル含有化合物

Country Status (7)

Country Link
US (3) US10112957B2 (enExample)
EP (2) EP3209648B1 (enExample)
JP (1) JP6788583B2 (enExample)
AU (1) AU2015335788B2 (enExample)
CA (1) CA2965178C (enExample)
IL (1) IL251790B (enExample)
WO (1) WO2016065138A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6878004B2 (ja) 2013-12-13 2021-05-26 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
KR102225840B1 (ko) * 2016-07-14 2021-03-11 일라이 릴리 앤드 캄파니 Jak 억제제로서의 피라졸릴아미노벤즈이미다졸 유도체
KR102540515B1 (ko) 2016-11-03 2023-06-05 코버스 파마슈티칼스, 인크. 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109265455B (zh) * 2018-11-09 2020-08-18 新发药业有限公司 一种达沙替尼的制备方法
CN115151537B (zh) * 2020-02-26 2024-09-06 株式会社大熊制药 制备杂环胺衍生物的方法
CN116348116A (zh) * 2020-03-06 2023-06-27 台湾卫生研究院 嘧啶化合物及其医药用途
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1999054286A2 (en) 1998-04-17 1999-10-28 Parker Hughes Institute Btk inhibitors and methods for their identification and use
CN1142912C (zh) 1998-08-04 2004-03-24 阿斯特拉曾尼卡有限公司 用作细胞因子产生的抑制剂的酰胺衍生物
ES2211172T3 (es) 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
MX2007007574A (es) 2004-12-22 2007-07-24 Astrazeneca Ab Derivados de piridina-carboxamida para uso como agentes anticancerosos.
JP2008528585A (ja) * 2005-01-26 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US7375951B2 (en) * 2006-07-07 2008-05-20 Lutron Electronics Co., Inc. Load control device having a split enclosure
CN101277689B (zh) 2005-08-08 2011-01-12 詹森药业有限公司 噻唑并嘧啶类激酶抑制剂
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007059157A1 (en) 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
WO2007076474A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
KR20100058660A (ko) 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
ES2396366T3 (es) 2007-12-10 2013-02-21 Concert Pharmaceuticals Inc. Inhibidores heterocíclicos de quinasas
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
EP2331506B1 (de) 2008-09-02 2013-07-03 Boehringer Ingelheim International GmbH Neue benzamide, deren herstellung und deren verwendung als arzneimittel
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8614234B2 (en) 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN102985426B (zh) 2010-07-13 2015-10-07 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
CA2832605C (en) 2011-05-23 2016-03-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US9023873B2 (en) 2011-10-03 2015-05-05 Syngenta Participations Ag Insecticidal 2-methoxybenzamide derivatives
AU2012318580A1 (en) 2011-10-04 2014-05-22 Gilead Calistoga Llc Novel quinoxaline inhibitors of PI3K
EA027561B1 (ru) 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
JP6117235B2 (ja) 2011-12-15 2017-04-19 ノバルティス アーゲー Ｐｉ３ｋの活性または機能の阻害剤の使用
CN103405429A (zh) 2013-08-22 2013-11-27 中国药科大学 一类vegfr-2抑制剂及其用途
WO2015069287A1 (en) 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
JP6878004B2 (ja) 2013-12-13 2021-05-26 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases

Also Published As

Publication number Publication date
WO2016065138A1 (en) 2016-04-28
CA2965178A1 (en) 2016-04-28
JP2017537886A (ja) 2017-12-21
IL251790B (en) 2019-08-29
US10844077B2 (en) 2020-11-24
CA2965178C (en) 2023-09-26
EP3209648B1 (en) 2020-03-11
EP3209648A4 (en) 2018-07-25
AU2015335788A1 (en) 2017-05-04
EP3715346B1 (en) 2024-01-03
US20170233411A1 (en) 2017-08-17
US10464949B2 (en) 2019-11-05
US20200165267A1 (en) 2020-05-28
AU2015335788B2 (en) 2020-07-30
IL251790A0 (en) 2017-06-29
US20190119301A1 (en) 2019-04-25
EP3209648A1 (en) 2017-08-30
EP3715346A1 (en) 2020-09-30
US10112957B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
JP6854762B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
JP6947651B2 (ja) ４，６−ピリミジニレン誘導体およびこれらの使用
US10730860B2 (en) Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP7028766B2 (ja) サイクリン依存性キナーゼの阻害剤
US12509455B2 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US10000483B2 (en) Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10844077B2 (en) Thiazolyl-containing compounds for treating proliferative diseases
JP2020055813A (ja) ジアゼパン誘導体の使用
JP2017504650A (ja) ジアゼパン誘導体およびその使用
JP2017512186A (ja) ジヒドロプテリジノン誘導体およびその使用
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
JP2022517740A (ja) サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201030

R150 Certificate of patent or registration of utility model

Ref document number: 6788583

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250